
    
      This is an open-label, phase 2 long-term study designed to evaluate the safety, local
      tolerability, pharmacokinetics and efficacy of sofpironium bromide gel when applied topically
      to the axillae.

      Subjects will apply the gel once daily at bedtime, to both axillae.

      A maximum of 24 subjects, will be enrolled to receive sofpironium bromide gel, 15%.

      Adverse events, vital signs, and local tolerability assessments will be collected at each
      visit. Urine pregnancy tests will be taken throughout the course of the study for women of
      child bearing potential. Blood and urine samples will be collected and analyzed for
      pharmacokinetics, routine hematology, chemistry, and urinalysis parameters at specified
      visits. Patient-reported outcome assessments will be recorded during the study at predefined
      time points.

      The study will be comprised of a total of 8 scheduled visits to take place over a 26 week
      period.
    
  